IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Burchardt, et al.

Application Serial No.: 09/701,313

Filed:

11/28/2000

Title:

Monoclonal Antibody and Assay for Detecting PIIINP

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 16, 2001

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING, COMPUTER READABLE COPY FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

Sir:

This replies to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on 30 April 2001. A copy of the Notice is enclosed.

Submitted herewith is a:

- 1. Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence Listing is assigned a separate identifier as required in 37 C.F.R. §1.821(c) and 37 C.F.R. §§1.822 and 1.823.
- 2. A copy of each Sequence Listing submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§1.821(e) and 1.824.
- 3. The computer readable form and paper copy submitted herewith are the same, and introduce no new matter over what is disclosed in the application (37 C.F.R. 1.821(g)).

Respectfully submitted,

Reg. No.: 41,670

Tel. No.: (203) 812-3964

Date: May 16, 2001

l∕errie L. Chiu

Aftorney for Applicant **Bayer Corporation** 400 Morgan Lane

West Haven, CT 06516

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

as of be
l as a' form
. t

Telephone: 703-305-3659

FORM PCT/DO/EO/920 (March 2001)

c. Oath or declaration of the inventors, in compliance with 37 CFR 1.49(a) and (b) preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.

The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.

d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$______ as a _____ large entity _____ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. [X] Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.

7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this respon			7.	
nclosed:	☐ PCT/DO/EO/917 ☐ PTO-875	PCT/DO/EO/920	Shakeel Ahmed	<u>.</u> : '
ORM P	CT/DO/EO/905 (March 2001) : T	Telephone: 703-305-3659	